Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor, with a median survival of 14--15 months \[[@B1]\]. GBM is primarily found in the brain, but it can also be found in other areas including the brain stem, cerebellum and spinal cord. A landmark Phase III study by Stupp *et al.* demonstrated that postsurgical radiotherapy with concomitant temozolomide (TMZ) chemotherapy (also known as the Stupp regimen) increases median survival by 2.5 months and results in a 37% reduction in death compared with radiotherapy treatment alone. This study also showed a direct relationship between methylation of the *MGMT* gene and TMZ response rate \[[@B2]\]. *MGMT* is a gene involved in the repair of highly mutagenic DNA changes. Thus, any damage to it leads to a cascade of uncontrolled mutations, which ultimately allows for subsequent targeting by alkylating agents like TMZ \[[@B3],[@B4]\]. But despite these advancements in treatments and better characterization of the genomic landscape, GBM still carries a highly aggressive and catastrophic prognosis. This is largely due to the poorly understood pathophysiology of GBM, as well as the lack of identifiable biologic targets to guide new therapies. There remains an unmet need to further unravel the pathophysiology of GBM and identify new biologic targets.

Recently, genomic profiling and The Cancer Genome Atlas project sequenced more than 600 genes from approximately 200 human samples \[[@B5]\]. GBM was also systematically studied by the Cancer Genome Atlas Research Network (TCGA) in detail. As a result of these studies, it was found that GBM has a complex genomic/proteomic signaling network, which is key to its rapid growth and differentiation. This network has the ability to adapt in response to certain targeted molecular treatments. Thus, the need for a comprehensive catalog of molecular alterations is of paramount importance. We hope that this understanding will help drive future investigations to further our understanding of GBM, as well as develop new patient-specific therapies \[[@B6]\].

Methods {#S0002}
=======

Patients {#S0003}
--------

Samples were obtained from 17 consecutive, newly diagnosed and pathologically confirmed GBMs in patients seen during 2017--2018 at Saint Luke's Hospital on the Plaza in Kansas City, MO, USA. Inclusion criteria were histopathologic confirmation of GBM, as well as the availability of proteomic and genomic analysis results. Patients without available genomic data were excluded. All patients in the sample had primary grade IV GBMs.

After initial diagnosis, standard treatment was initiated. This included optimal surgical resection and subsequent adjuvant radiotherapy and chemotherapy (with TMZ) at a daily dose of 150--200 mg/m^2^ of body surface area for 5 days. This scheme was then repeated on a 28-day cycle \[[@B4]\]. Both clinical and diagnostic/radiological evaluation were subsequently used to determine disease progression as well as incidence of relapse. MRI of the brain before and after treatment was utilized in diagnostic evaluation and assessment of treatment response. The tumor samples utilized for proteogenomic analysis were those obtained at time of initial biopsy and diagnosis; no samples from recurrent tumors were analyzed.

Tumor specimens were collected surgically for all 17 patients with newly diagnosed GBM. For each patient, an initial sample for intraoperative frozen section was obtained. Subsequently, optimal tumor resection was performed. For patients undergoing total or near-total resection, tumor samples in their entirety were sectioned and reviewed for histopathology. For some patients, tissue samples were obtained as separate fragments. If complete or partial resection was not possible, core biopsies were obtained and then analyzed. Details regarding surgical practices utilized and tumor samples obtained have been included as [Supplementary Table 1](/doi/suppl/10.2217/cns-2019-0003/suppl_file/suppl/cns-08-37-s1.docx). Sections with histopathological confirmation of GBM were then sent for proteogenomic analysis.

Tumor cells for analysis were obtained through a pathologist-directed laser microdissection system by methods defined previously by Hembrough *et al.* \[[@B7]\]. Areas for microdissection were included in the original individual analysis report as an image. Analysis was performed using molecular fingerprinting by GPS Cancer™, NantWorks (CA, USA). DNA and RNA were extracted from preserved tissues. DNA sequencing libraries were prepared for each tumor sample and a matched-normal sample. Tumor versus matched-normal variant analysis was performed using NantOmics Contraster analysis pipeline to determine somatic and germline single nucleotide variants, insertions, deletions and identify highly amplified regions of the tumor genome. RNA-sequencing libraries were similarly prepared for the tumor sample. Sequencing using the Illumina platform in a NantOmics clinical laboratory improvement amendments and certified authorization profession-certified sequencing laboratory was performed. Quantitative proteomic analysis as well as genomic analysis was reported \[[@B8]\].

MGMT methylation and other biomarkers (chemotherapy response markers, chemotherapy resistance markers, prognostic markers) were scanned from tumor and normal tissues using the laser microdissection system. Genomics were analyzed to look for alterations in known oncogenes, tumor-suppressor genes, potentially treatable genes, tumor mutation burden, variants and disruptive germline alterations (including frame-shifting, insertions, deletions, nonsense and missense). Gene type was obtained by using data from the COSMIC Cancer Gene Census. Clusters of mutations were discovered using OncodriveCLUST on the Five3 variant calls made on more than 5000 TCGA tumor exomes \[[@B9],[@B10]\]. Secondary screening for cancer predisposition was completed according to ACMG's recommendations for incidental findings \[[@B11]\]. Microsatellites consisting of homopolymer repeats were analyzed for a statistically significant increase in the number of length polymorphisms in tumor and normal sample to identify instability. The percentage of unstable loci is calculated for the tumor and matched-normal. The differential is then determined by subtracting the percentage of unstable loci in the normal sample from the percentage of unstable loci calculated in the tumor. A tumor is considered to demonstrate microsatellite instability when the differential exceeds the threshold. The number of length polymorphisms for each microsatellite locus was computed across approximately 5000 blood and solid normal exomes sequenced by TCGA comprising 18 different cancer types \[[@B12]\]. Loci covered by fewer than 30 reads were excluded from the analysis. Potential functional fusions were identified by using transcriptome aligned RNA sequencing data, using clusters of spanning reads between two transcripts where one of the transcripts belongs among the 74 commonly found genes in oncogenic fusions.

'My Cancer Genome' is an online tool that considers disease-relevant human genes, drugs, drug--gene interactions and potential druggability, including 835 drug--gene interactions between 226 drugs and 169 target genes \[[@B13],[@B14]\]. Our proteogenomic analysis utilized this resource and reported potentially activating alterations (missense mutations, in-frame deletions and amplifications) in this panel of 169 'druggable' genes; a druggable or 'treatable' gene is defined as a gene against which at least one of 226 FDA approved or investigational drugs have demonstrated activity. This includes reporting the presence of genomics-based targets indicated on drug labels for 21 FDA-approved drugs \[[@B15],[@B16]\]. Alterations that disrupt a gene were not considered treatable; as the genes must be functional for a drug to have an effect \[[@B10]\]. Variants produced from sequencing data of tumor sample (vs matched normal) were also scanned for evidence of resistance biomarkers for six drugs including cetuximab, dasatinib, imatinib mesylate, panitumumab, crizotinib and tamoxifen \[[@B16]\]. Known tumor genes were classified as tumor suppressors or oncogenes using data available from Cosmic Cancer Gene Census \[[@B14]\].

Data analysis {#S0004}
-------------

Retrospective analysis of patients' biomarkers, *MGMT* methylation, mutation burden, microsatellite instability and fusion findings were completed and then correlated to their respective 'overall survival' (OS). OS was defined as duration of survival after the initial diagnosis was made. 'Progression-free survival' (PFS) was defined as the time during and after treatment when the disease did not progress, or when death was caused by any other reason aside from the tumor itself. Alteration-driven treatment after thorough review from different literatures was provided to the appropriate patients and their responses were observed. Baseline demographic data including age at the time of diagnosis as well as gender was retrospectively collected from patients' medical records.

Results {#S0005}
=======

As summarized in [Tables 1](#T1){ref-type="table"} & [2](#T2){ref-type="table"}, the dataset contains clinical and proteogenomic data from 17 patients. The same technological and laboratory modalities were utilized for each of these patients.

###### Patient characteristics (n = 17).

  -------------------------------------------------- -------------------------------------------
  **Age at diagnosis:**\                             **Years:**\
  -- Median\                                         -- 56\
  -- Minimum\                                        -- 20[^†^](#T1TFN1){ref-type="table-fn"}\
  -- Maximum                                         -- 72[^†^](#T1TFN1){ref-type="table-fn"}

  **Gender:**\                                       **Number of patients:**\
  -- Male\                                           -- 8\
  -- Female                                          -- 9

  **Overall survival:**\                             **Months:**\
  -- Minimum\                                        -- 5\
  -- Maximum\                                        -- 28[^†^](#T1TFN1){ref-type="table-fn"}\
  -- Range                                           -- 23

  **Clinical status:**\                              **Number of patients**\
  -- Living\                                         -- 13\
  -- Deceased                                        -- 4

  **Number of relapses:**\                           **Number of patients:**\
  -- Zero\                                           -- 12\
  -- One\                                            -- 4\
  -- Two                                             -- 1

  **No. of treatment lines:**\                       **Number of patients:**\
  -- One\                                            -- 12\
  -- Two\                                            -- 4\
  -- Three                                           -- 1

  **No. receiving:**\                                **Number of patients:**\
  -- Temozolomide\                                   -- 17 (100)\
  -- Avastin\                                        -- 5 (29)\
  -- Irinotecan\                                     -- 4 (23.5)\
  -- Carboplatin\                                    -- 1 (0.06)\
  -- Lomustine\                                      -- 1 (0.06)\
  -- Radiotherapy\                                   -- 17 (100)\
  -- Surgical resection                              -- 17 (100)

  **Patients with:**\                                **Number of patients:**\
  -- High mutation burden\                           -- 1\
  --*TP53* mutation\                                 -- 5 (29%)\
  --*EGFR* mutation\                                 -- 7 (41.2%)\
  -- Proteomic MGMT\                                 -- 13 (76%)\
  -- Genetic cancer predisposition screen positive   -- 1 (*MSH6*, frameshift mutation)
  -------------------------------------------------- -------------------------------------------

Living.

###### Biomarkers and survival status of patients (n = 17).

  Patient number   Proteomic MGMT   Proteomic EGFR   *G-EGFR*   *G-p53*   OS (months)   Current status
  ---------------- ---------------- ---------------- ---------- --------- ------------- ----------------
  1                Present                           Present              7             Alive
  2                Present          Present                               15            Alive
  3                Present                                      Present   8             Alive
  4                Present                           Present              10            Alive
  5                Present                                      Present   11            Alive
  6                                                  Present              10            Deceased
  7                Present                           Present              11            Alive
  8                                                             Present   28            Alive
  9                Present          Present                               11            Alive
  10               Present          Present                               11            Alive
  11               Present          Present          Present              12            Alive
  12               Present          Present                               25            Alive
  13                                Present                     Present   5             Deceased
  14               Present          Present          Present              17            Deceased
  15               Present          Present                     Present   10            Deceased
  16                                                 Present              10            Alive
  17               Present          Present                               8             Alive

Amplification and overexpression of the *EGFR* gene is a distinct feature of GBM, noticed in 40% of these tumors. Table shows discrepancy between frequency of proteomic expression (9/17) and genomic mutation of EGFR (7/17), with overlap between the two in only 2/17 cases. No clear relationship has been found between the p53 pathway with treatment and outcome of GBM.

GBM: Glioblastoma multiforme; G-*EGFR*: Presence of *EGFR* mutation on genomic analysis; *G-P53*: Presence of *TP53* mutation on genomic analysis; OS: Overall survival.

Patient characteristics {#S0006}
-----------------------

17 patients newly diagnosed with GBM were included in the study. Nine (n = 9) patients were females (53%). The median age was 56 (range 20--72 years). Clinical and demographic characteristics of the study population are summarized in [Table 1](#T1){ref-type="table"}.

All patients underwent surgical resection: 9/17 patients had gross total resection, 4/17 patients had near total or partial resection and the remaining 4/17 had biopsy samples taken either stereotactically or via Burr-hole. Despite standard therapy being given to all patients, 5/17 relapsed. Following relapse, four of these patients were then treated with second-line therapy with Avastin and Irinotecan. One patient was treated with TMZ and Avastin.

13 out of 17 (76%) patients were alive at time of completion of this study. The median OS was found to be 12.29 months. Five months was the lowest survival observed. For this patient, genetic aberrations included: *TP53* missense mutation,*SPEN* nonsense mutation and *H3F3A* missense mutation.

Genomic alterations {#S0007}
-------------------

Pathogenic gene mutations detected in study participants included *TP53*, *EGFR*, *NOTCH1*, *RAD21* and *SYNE1* (missense mutations); *SPEN*, *DEPDC5*, *STAG2*, *TPR*, *USP9X*, *MAGED1*, *ARHGAP5*, *CTDNEP1*, *ARID1A* and *BCOR* (nonsense mutations); *PTEN* and *ATRX* (frame-shift mutations); and *PIK3R1*, *CHD8* and *CSMD3* (in-frame deletions).

Likely pathogenic mutations noted were *IDH1*, *RET*, *PPP2R1A*, *PGM5*, *ZNF117*, *ACVR1*, *EPHA6*, *ZNF479*, *ZNF117*, *ZNF181*, *ZFP2*, *MS4A8*, *IL5RA*, *MKRN1*, *CD163*, *ATPB3*, *KLK8*, *COBLL1*, *CHD8*, *GRXCR1*, *ABCB1* and *H3F3A* (missense mutations); *KIAA1109*, *NBPF1*, *AMBRA1*, *COL5A2* and *RBM10* (splice site mutation) and *CHD3* (in-frame deletion).

Key tumor-suppressor genes detected included *TP53*, *SPEN*, *FBXO11*, *ARID1A*, *PIK3R1*, *BCOR*, *NOTCH1*, *ATRX*, *PTEN*, *CDKN2A*, *NF1 STAG2*, *RB1* and *RAD21*. Known oncogenes identified included *EGFR*, *RET*, *IDH1*, *SOX2*, *GNAS*, *H3F3A*, *ACVR1*, *PPP2R1A*, *RPL5* and *ATP2B3*. These findings are summarized in [Table 3](#T3){ref-type="table"}, which depicts major types of mutations for each of the 17 patients included in the study and whether these were pathogenic, likely pathogenic or of unknown clinical significance. It also identifies potential 'treatable' genes. [Table 4](#T4){ref-type="table"} summarizes the frequency of major mutations seen and highlights the major pathways these genes are involved in. Such pathways may be altered as a result of these mutations.

###### Alterations in top-ranked known oncogenes, tumor suppressor genes and/or treatable genes detected for each of 17 samples.

  Genetic mutation   Patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ------------------ --------------------------------------------- ------------------------------------------ ------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------------------------------- ------------------------------------------- ------------------------------------------------------ ------------------------------------------------ ------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------
  Nonsense           ARHGAP5[^‡^](#T3TFN2){ref-type="table-fn"}    SPEN[^‡^](#T3TFN2){ref-type="table-fn"}    ARID1A[^‡^](#T3TFN2){ref-type="table-fn"}   DEPDC5[^‡^](#T3TFN2){ref-type="table-fn"}   GRHPR                                                                           CTDNEP1[^‡^](#T3TFN2){ref-type="table-fn"}                                     USP9X[^‡^](#T3TFN2){ref-type="table-fn"}     COL3A1                                      PDZD2                                                  RPS16                                            TPR[^‡^](#T3TFN2){ref-type="table-fn"}      STAG2[^‡^](#T3TFN2){ref-type="table-fn"}    KDM4E                                                                           RAVER2                                      OR52N1                                                                            PCDH11X                                       MAGED1[^‡^](#T3TFN2){ref-type="table-fn"}
                     MEGF8                                                                                    BCOR[^‡^](#T3TFN2){ref-type="table-fn"}     ABCB1[^†^](#T3TFN1){ref-type="table-fn"}                                                                                    KRT33B                                                                         CDKN2A [^‡^](#T3TFN2){ref-type="table-fn"}                                                                                                      KEL                                              DNAH6                                       PIEZ02                                      RPL5                                                                            SAGE1                                                                                                                         CHUK                                          RAB5A
                                                                                                              DPT                                         HYDIN                                                                                                                       VAT1L                                                                          NF1[^‡^](#T3TFN2){ref-type="table-fn"}                                                                                                                                                                                                       NBPF15                                                                                                                      COX6B2                                                                                                                        HMCN1                                         ZSWIM1
                                                                                                              ARGFX                                       MGME1                                                                                                                       HAPLN1                                                                         THSD7B                                                                                                                                                                                                                                       TTC3                                                                                                                        USP17L11                                                                                                                                                                    ELMOD3
                                                                                                              PDE4DIP                                     HECW2                                                                                                                       PHF21A                                                                         SCAF11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               CFTR
                                                                                                              RTKN                                        SRGAP1                                                                                                                      MUC19                                                                          RAPGEF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               COL7A1
                                                                                                                                                                                                                                                                                                                                                                     JMJD4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                COL9A1
                                                                                                                                                                                                                                                                                                                                                                     CEP83                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                     NT5DC1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                     PHLDA2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Missense           GNAS[^†^](#T3TFN1){ref-type="table-fn"}       TP53[^‡^](#T3TFN2){ref-type="table-fn"}    ACVR1[^†^](#T3TFN1){ref-type="table-fn"}    WDR90                                       NOTCH1[^‡^](#T3TFN2){ref-type="table-fn"}                                       TP53[^†^](#T3TFN1){ref-type="table-fn"}                                        MS4A8[^†^](#T3TFN1){ref-type="table-fn"}     KLK8[^†^](#T3TFN1){ref-type="table-fn"}     1DH1[^†^](#T3TFN1){ref-type="table-fn"}                TP53[^†^](#T3TFN1){ref-type="table-fn"}          PIK3R1[^§^](#T3TFN3){ref-type="table-fn"}   EGFR[^‡^](#T3TFN2){ref-type="table-fn"}     PPPR2R1A[^†^](#T3TFN1){ref-type="table-fn"}                                     RAD21[^‡^](#T3TFN2){ref-type="table-fn"}    IDH1[^†^](#T3TFN1){ref-type="table-fn"}                                           SYNE1[^‡^](#T3TFN2){ref-type="table-fn"}      EGFRp.R324L[^‡^](#T3TFN2){ref-type="table-fn"}
                     ZNF479[^†^](#T3TFN1){ref-type="table-fn"}     H3F3A[^†^](#T3TFN1){ref-type="table-fn"}   FAM47A                                      ABCA7                                       EGFR[^§^](#T3TFN3){ref-type="table-fn"}^,^[^†^](#T3TFN1){ref-type="table-fn"}   EPHA6[^†^](#T3TFN1){ref-type="table-fn"}                                       IL5RA[^†^](#T3TFN1){ref-type="table-fn"}     ZNF181[^†^](#T3TFN1){ref-type="table-fn"}   TP53[^†^](#T3TFN1){ref-type="table-fn"}                PHLDA1                                           NLGN1                                       CHD8[^†^](#T3TFN1){ref-type="table-fn"}     EGFR[^§^](#T3TFN3){ref-type="table-fn"}^,^[^†^](#T3TFN1){ref-type="table-fn"}   ATP2B3[^†^](#T3TFN1){ref-type="table-fn"}   TP53[^†^](#T3TFN1){ref-type="table-fn"}                                           PGM5[^†^](#T3TFN1){ref-type="table-fn"}       EGFRp.G598V[^‡^](#T3TFN2){ref-type="table-fn"}
                     POTEF                                         PTPRK                                      MAP3K4                                      CDC42BPB                                    FBX011                                                                          KIAA1109[^†^](#T3TFN1){ref-type="table-fn"}                                    MKRN1[^†^](#T3TFN1){ref-type="table-fn"}     DCAF12L2                                    PRKRIR                                                 TBX3                                             FAM83A                                      GRXCR1[^†^](#T3TFN1){ref-type="table-fn"}   EVPL                                                                            RBBP6                                       CD163[^†^](#T3TFN1){ref-type="table-fn"}                                          ZNF117[^†^](#T3TFN1){ref-type="table-fn"}     EGFRp.R108K[^†^](#T3TFN1){ref-type="table-fn"}
                     TNFRSF10C                                     FBX011                                     BIRC6                                       TNRC18                                      ZNF335                                                                          RET[^§^](#T3TFN3){ref-type="table-fn"}^,^[^†^](#T3TFN1){ref-type="table-fn"}   OR2T33                                       MYLK4                                       DFNA5                                                  KDM5C                                            DHCR24                                      KIAA0907                                    NOTCH2                                                                          WRN                                         SCML4                                                                             KMT2C                                         EGFRp.T363A[^†^](#T3TFN1){ref-type="table-fn"}
                     DOCK2                                         DLG2                                       NR2E1                                       RADIL                                       SPATA2L                                                                         NBPF1p.L943V[^†^](#T3TFN1){ref-type="table-fn"}                                TMEM132D                                     NAV1                                        AQP5                                                   BCOR                                             COBLL1                                      CD5L                                        FAM47B                                                                          MME                                         CTDNEP1                                                                           SRSF1                                         ZNF117
                     ADAMTS10                                      CASR                                       CSNK1A1                                     LPAR1                                       XKR7                                                                            NBPF1p.N114S[^†^](#T3TFN1){ref-type="table-fn"}                                RYR2                                         MEN1                                        ZNF469                                                 OR2A25                                           FAM72D                                      PPM1K                                       BLM                                                                             ZNF91                                       SP7                                                                               DOPEY1                                        ZFP2
                     NUMA1                                         ANP32E                                     BTD                                         JAG2                                        VWF                                                                             AMBRA1[^†^](#T3TFN1){ref-type="table-fn"}                                      NETO1                                        MUC7                                        RRN3                                                   GPC3                                             SIGLEC9                                     TTC37                                       KRT72                                                                           CENPB                                       CFH                                                                               HNF4G                                         OR2M7
                     OGT                                           UIMC1                                      TPTE                                        SLC39A12                                    CD19p.R514C                                                                     NBPF1p.S340F[^†^](#T3TFN1){ref-type="table-fn"}                                ZFHX3                                        ATRX                                        ATAD3B                                                 COG1                                             TSPAN8                                      AQP10                                       ARAP3                                                                           DCAF12L2                                    TLR4                                                                              HCN1                                          SYNE1
                     DACH1                                         TMCC1                                      DNAH5                                       SIGLEC7                                     PRR23A                                                                          ZNF91                                                                          CPEB2                                        GCNT1                                       PCNT                                                   FLNA                                             UGT2A2                                      RB1                                         ZNF469                                                                          NR4A3                                       ERCC6                                                                             CDC27                                         KCNK9
                     CPNE7                                         NOV                                        BCAR3                                       SPATA13                                     SLC30A4                                                                         LEPR.pF898L                                                                                                                 COG3                                        NCF1                                                   TRIM3                                            AMPH                                        RIMS2                                       TBXAS1                                                                          OPLAH                                       GTF2B                                                                             ZNF705B                                       HNF1A
                     ZNF91                                         SH2D4B                                     ASCL1                                       DOK5                                        LOXL4                                                                           LEPR.pH924P                                                                                                                 CACNA1C                                     GPR12                                                  TRIM49B                                          VCX3A                                       F5                                          LRWD1                                                                           TARS                                        GEM                                                                               CNTNAP3                                       CDH1
                                                                   MYO18B                                     SALL3                                       PADI6                                       MCCp.G20S                                                                       NPHS2                                                                                                                       SVILp.P809A                                 SPOPL                                                  MAP1B                                            DNAH14                                      NIPBL                                       CENPB                                                                           RRN3                                        PLEC                                                                                                                            ZNF107
                                                                   TDRD6                                      FGF2                                        ZNF92                                       LHX5                                                                            GOLGA6B                                                                                                                     SVILp.L948R                                 DNAAF1                                                                                                  PCDHB7                                      KRT7                                        FBXL18                                                                          TUBA3D                                      METTL4                                                                                                                          DIP2C
                                                                   CEP290                                     INO80D                                      KCNH2                                       SLC37A4                                                                         DIDO1                                                                                                                       TMPRSS13                                    SVOP                                                                                                    LRP2                                        TYW1B                                       ZNF831                                                                          CROCC                                       ZNF257                                                                                                                          DNM2
                                                                   CYP7B1                                     TRIM22                                      SULT1A4                                     MCCp.G23S                                                                                                                                                                                                                                                                                                                                                       PAXIP1                                      MUC12                                       LIN37                                                                           FLG                                         TBX22                                                                                                                           1L16
                                                                   TTN                                                                                                                                CD19p.G41A                                                                                                                                                                                                                                                                                                                                                      PTPRQ                                       MCM2                                        EXOC4                                                                           GPAT2                                       HERC2                                                                                                                           AOAH
                                                                   WSCD2                                                                                                                              NHSL1                                                                                                                                                                                                                                                                                                                                                           EEF2                                        OR6B3                                       CRNN                                                                            ZNF708                                      DDY28                                                                                                                           PCDHA4
                                                                   TERF1                                                                                                                              GCNT2                                                                                                                                                                                                                                                                                                                                                           SVIL                                        C5ORf60                                     ZAN                                                                                                                         LAMA3                                                                                                                            
                                                                   CACNB4                                                                                                                             RGP1                                                                                                                                                                                                                                                                                                                                                            BCR                                                                                     AQP1                                                                                                                        CTSG                                                                                                                             
                                                                   HOXA3                                                                                                                              ZNF407                                                                                                                                                                                                                                                                                                                                                          BASP1                                                                                   ANKS4B                                                                                                                      PDE6B                                                                                                                            
                                                                   GANC                                                                                                                               PER1                                                                                                                                                                                                                                                                                                                                                                                                                                                    TRAPPC10                                                                                                                    CNTNAP4                                                                                                                          
                                                                   CSMD1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  PHF20                                                                                                                            
  Frame shift        NPAS2                                         TRIM37                                     DDX10                                       FOXD1                                       FOXD1                                                                           CSMD3[^‡^](#T3TFN2){ref-type="table-fn"}                                       USP3                                         ADAMTS7                                     ATRX[^‡^](#T3TFN2){ref-type="table-fn"}                PTEN[^‡^](#T3TFN2){ref-type="table-fn"}          PAPSS2                                      PTEN[^‡^](#T3TFN2){ref-type="table-fn"}     HMCN2                                                                                                                       ATRX[^‡^](#T3TFN2){ref-type="table-fn"}                                           LRRK1                                          
                                                                   RAD51AP2                                   SPATA31D1                                   ANKLE1                                      SLC16A9                                                                         CCDC121                                                                        C3                                                                                       NKX2-2                                                 CDKN2A[^‡^](#T3TFN2){ref-type="table-fn"}        ZZEF1                                       WDHD1                                                                                                                                                                                                                                                     ANAPC4                                         
                                                                                                                                                          NLRP5                                                                                                                       DYNC2H1                                                                        TPI1                                                                                     TRIM64B                                                VGLL3                                                                                        KHSRP                                                                                                                                                                                                                                                     CCDC65                                         
                                                                                                                                                                                                                                                                                      ADAMTS7                                                                                                                                                                 HGC6.3p. Q151Tfs[^†^](#T3TFN1){ref-type="table-fn"}7   GOLGA4                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                      NBPF12                                                                                                                                                                  HGC6.3p. Q151Hfs[^†^](#T3TFN1){ref-type="table-fn"}7   PIGP                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                              GABRG2                                                 FOXD1                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                              SAA1                                                   MSI2                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                              SAA2-SAA4                                              CRCP                                                                                                                                                                                                                                                                                                                                                                                                  
  Splice site        COL5A2[^†^](#T3TFN1){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                    CHD9                                                                                               LYPD4                                                                                                                                                                                                                                                                                                                                                  HELQ                                          STAG2[^‡^](#T3TFN2){ref-type="table-fn"}
                     RBM10[^†^](#T3TFN1){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                     WDR45B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                     ARAP2                                                                                                                                                                                                                                                                                                                                                                                        LRRC37B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                     EIF3J                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                     ELAVL3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                     TMEM150A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Amplification      EGFR                                                                                                                                                                                                                                                             GNAS                                                                                                                        EGFR                                                                                                                                                                                            EGFR[^§^](#T3TFN3){ref-type="table-fn"}                                                                                                                                                                                                                                                                  
                     WBSCR17                                                                                                                                                                                                                                                          SOX2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Fusion             EGFRvIII[^§^](#T3TFN3){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                     FGFR3-TACC3                                  EGFR-SEPT14                                                                                        NOTCH1-AGPAT2                                                                                                                                                                                                                                                                                                                                          EGFRvIII[^§^](#T3TFN3){ref-type="table-fn"}    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     FGFR3-TACC3[^§^](#T3TFN3){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                        
  Truncation                                                       SPEN                                       ARID1A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              PTEN                                                                                                                                                                                                                                                                                                     
                                                                                                              BCOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                STAG2                                                                                                                                                                                                                                                                                                    
  Inframe deletion                                                                                            PIK3R1[^§^](#T3TFN3){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                       KRTAP5-5                                                                                                GIGYF2                                                                                  NPIPB5                                                                          CHD8[^‡^](#T3TFN2){ref-type="table-fn"}     PIK3R1[^§^](#T3TFN3){ref-type="table-fn"}^,^[^‡^](#T3TFN2){ref-type="table-fn"}                                                  
                                                                                                              ZMIZ1                                                                                                                                                                                                                                                                                                                                           MNX1                                                                                                                                                                                                                                                                            CHD3[^†^](#T3TFN1){ref-type="table-fn"}                                                                                                                                      

Each column depicts genetic mutation profile for individual patients with glioblastoma multiforme, classified by the type of mutation. Mutations are further classified as pathogenic or likely pathogenic, suggesting these mutations likely have a role in tumorigenesis. Availability of an FDA-approved or investigational drug targeting a potentially 'treatable' gene is also depicted.

Pathogenic.

Likely pathogenic.

Treatable genes detected in this cohort.

###### Frequency of detected mutations in known tumor-suppressor genes and known oncogenes and RNA fusions along with potentially altered pathways.

  -----------------------------------------------------------------------------------------------------------
  Mutations                                 Frequency   Pathway
  ----------------------------------------- ----------- -----------------------------------------------------
  **Known tumor-suppressor genes:**\        \           \
  *-- TP53\                                 5/17\       p53 pathway\
  -- PIK3R1\                                3/17\       PI3K signaling\
  -- FBXO11\                                3/17\       Ubiquitination\
  -- ATRX\                                  3/17\       Genome integrity\
  -- CKDN2A\                                2/17\       Rb pathway\
  -- PTEN\                                  2/17\       PI3K signaling\
  -- TBX3\                                  2/17\       Transcription repression\
  -- BCOR\                                  2/17\       Transcription corepression, BCL6 pathway\
  -- STAG2\                                 2/17\       Cell division, chromatids separation\
  -- SPEN\                                  1/17\       DNA repair and mitosis\
  -- ARID1A\                                1/17\       Chromatin remodeling\
  -- RB1\                                   1/17\       RB pathway\
  -- NOTCH1\                                1/17\       Ligand-activated transcription\
  -- NOTCH2\                                1/17\       Transcriptional coactivation\
  -- NF1\                                   1/17\       MAPK signaling\
  -- MEN1\                                  1/17\       Transcription regulation\
  -- GPC3\                                  1/17\       Wnt pathway\
  -- KDM5C\                                 1/17\       Transcription regulation/chromatin remodeling\
  -- BLM1\                                  1/17\       DNA repair\
  -- RAD21\                                 1/17\       RB1 pathway\
  -- KMT2C*                                 1/17        Transcriptional coactivation

  **Known oncogenes:**\                     \           \
  **-- EGFR**\                              7/17\       \
  *-- EGFR* variant III (RNA fusion)\       2/17\       RTK signaling\
  *-- EGFR* Amplification\                  3/17\       RTK signaling\
  *-- EGFR p.L62R*\                         1/17\       RTK signaling\
  *-- EGFR (p.L861Q)*\                      1/17\       RTK signaling\
  *-- EGFR (p.N842K)*\                      1/17\       RTK signaling\
  *-- IDH1*\                                2/17\       Metabolism\
  *-- RET*\                                 1/17\       MAPK and PI3K signaling\
  *-- GNAS*\                                1/17\       GPCR pathways\
  *-- PPP2R1A*\                             1/17\       GSK3β, Akt and mTOR signaling\
  *-- SOX2*\                                1/17\       Transcription regulation\
  *-- ACVR1*\                               1/17\       BMP/TGF-β signaling pathway\
  *-- H3F3A*\                               1/17\       Post-translational modification\
  *-- RPL5*\                                1/17\       Ribosomal formation\
  *-- ATP2B3*                               1/17        Calcium transport

  **RNA fusions:**\                         \           \
  *-- EGFR* variant III\                    2/17\       RTK signaling\
  *-- FGFR3-TACC3*\                         2/17\       RTK signaling\
  *-- NOTCH1-AGPAT2*\                       1/17\       Notch signaling\
  *-- EGFR-SEPT14*                          1/17        RTK signaling

  **Others:**\                              \           \
  -- High-tumor exonic mutational burden\   1/17\       Mismatch repair\
  *-- MSH6* frameshift detected\            1/17\       DNA repair\
  *-- MGMT* methylation\                    13/17\      DNA repair\
  -- Proteomic *EGFR*                       9/17        Proteomic expression higher than genomic expression
  -----------------------------------------------------------------------------------------------------------

The TP53 pathway was dysregulated in 5/17 patients (29%). One patient had *p53* mutation in PI3K pathway. At the RNA level, *p53* mutations were noticed in COSMIC hotspot driver gene and accompany *IDH1* and *ATRX* mutations in two patients. This suggests the transformation from low- to high-grade glioma. Three patients had coexisting *RET, SPEN and CDK2NA* mutations, respectively, with a *p53* mutation. In contrast to proteomic expression, we noticed significant heterogeneity of EGFR expression on genomic platform. *EGFR* alterations were noticed in 7/17 patients (41.2%). Two of them showed EGFR variant III fusion. These mutations were accompanied by DNA amplification with multiple mutation allele frequencies. One patient had *L816Q EGFR* missense mutation on exon 21 which is commonly seen in lung cancer patients, who respond specifically to EGFR inhibitors.

Treatable genes were identified. Three out of 17 patients showed *PIK3R1*, 7/17 showed *EGFR* and 1/17 showed *RET* as treatable genes. These are summarized along with potential targeted therapeutic agents in [Table 5](#T5){ref-type="table"}.

###### Treatable genes detected and potential targeted therapy options.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatable gene                    Targeted treatment
  --------------------------------- -----------------------------------------------------------------------------------------------------------------------
  *PIK3R1*:                         

  -- p.T576del                      BKM120 (investigational drug)

  -- p.G376R                         

  -- p.R465del                       

  *EGFR* amplification              Vandetanib, gefitinib, erlotinib, cetuximab, panitumumab, afatinib (FDA approved for other indications)\
                                    TXL647, MM151, SYM004, MEHD7945A, CO-1686, AZD8931, necitumumab, nimotuzumab, icotinib, dacomitinib (investigational)

  *EGFR* variant III (RNA fusion)   Dacomitinib, rindopepimut, aNK-EGFR

  *EGFR* p.L62R                     Vandetanib, gefitinib, erlotinib, cetuximab, panitumumab, afatinib (FDA approved for other indications)\
                                    Nimotuzumab, icotinib, dacomitinib, AZD8931 (investigational)

  *EGFR* (p.L861Q)                  Vandetanib, gefitinib, erlotinib, cetuximab, panitumumab, afatinib (FDA approved for other indications)\
                                    TXL647, MM151, SYM004, MEHD7945A, CO-1686, AZD8931, Necitumumab, Nimotuzumab, Icotinib, Dacomitinib (investigational)

  *EGFR* (p.N842K)                  Vandetanib, gefitinib, erlotinib, cetuximab, panitumumab, afatinib (FDA approved for other indications)\
                                    Nimotuzumab, icotinib, dacomitinib (investigational)

  *RET* (p.H840--841delinsQT)       Vandetanib, sunitinib, regorafenib, sorafenib, cabozantinib
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

FDA: Food and Drug Administration.

Proteomic expression {#S0008}
--------------------

Biomarkers analyzed in this study included hENT1, ERCC1, TUBB3, MGMT, PDL1, EGFR, FGFR1234, HER3, AXL, IDO1 and RRM1 proteins. KRAS, p16 and tissue Ki-67 were also analyzed. Only a single patient demonstrated high mutation burden, and this patient is still currently alive with an overall survival of 8 months. 9 out of 17 patients had proteomic expression of EGFR out of which only two showed its coinciding genomic expression. Mutation burden was found to be low in all patients except for one. 13 out of 17 (76%) biopsies showed MGMT methylation. [Table 6](#T6){ref-type="table"} provides a detailed proteomic profile that was available for 13/17 patients. This includes presence or absence of different biomarkers on analysis including chemotherapy response markers, chemotherapy resistance markers, prognostic markers and biomarkers against which FDA-approved drugs may be available (for GBM or non-GBM indications) or may currently be in clinical trial phase.

###### Proteomic landscape of patients with glioblastoma multiforme (n = 13/17).

                                      Proteins    Patient number (n = 13)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ----------------------------------- ----------- --------------------------------------- -------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- ---------------------------------------
  Targeted therapy response markers   EGFR        D[^†^](#T6TFN1){ref-type="table-fn"}    D                                      D[^†^](#T6TFN1){ref-type="table-fn"}    D                                       D                                       D[^†^](#T6TFN1){ref-type="table-fn"}    D[^†^](#T6TFN1){ref-type="table-fn"}    D                                       D[^†^](#T6TFN1){ref-type="table-fn"}    D[^†^](#T6TFN1){ref-type="table-fn"}    D                                       D[^†^](#T6TFN1){ref-type="table-fn"}    D[^†^](#T6TFN1){ref-type="table-fn"}
                                      ALK         ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      AR          ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      HER2        ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      PDL1        ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                      ND                                      ND
                                      ROS1        ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      RET         ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
  Chemotherapy response markers       hENT1       D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                     D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                      ND                                      ND                                      ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                      D                                       D[^†^](#T6TFN1){ref-type="table-fn"}
                                      Fr-alpha    ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      TOPO1       D                                       D                                      D                                       D                                       D                                       D                                       D                                       D                                       ND                                      ND                                      D                                       ND                                      D
                                      TOPO2A      ND                                      D                                      ND                                      D                                       ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      TYMP        ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      D                                       ND                                      ND                                      D                                       D                                       D                                       ND
  Chemotherapy-resistance markers     MGMT        D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}
                                      ERCC1       ND[^†^](#T6TFN1){ref-type="table-fn"}   D[^‡^](#T6TFN2){ref-type="table-fn"}   D[^‡^](#T6TFN2){ref-type="table-fn"}    ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}   D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    ND[^†^](#T6TFN1){ref-type="table-fn"}   ND[^†^](#T6TFN1){ref-type="table-fn"}
                                      TUBB3       D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}   D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}    D[^‡^](#T6TFN2){ref-type="table-fn"}
                                      RRM1        D                                       D                                      D                                       ND                                      D                                       ND                                      ND                                      ND[^†^](#T6TFN1){ref-type="table-fn"}   D                                       ND[^†^](#T6TFN1){ref-type="table-fn"}   D                                       D                                       D[^‡^](#T6TFN2){ref-type="table-fn"}
  Clinical trial response markers     FGFR-1234   ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}   ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                      ND                                      ND
                                      Her3        ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}   ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      AXL         ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                      ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                      ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}
                                      IDO1        ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      D[^†^](#T6TFN1){ref-type="table-fn"}    ND                                      ND                                      ND                                      ND                                      ND
                                      IGF1R       ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      MET         ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
                                      MSLN        ND                                      ND                                     ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND                                      ND
  Prognostic markers                  KRAS        D                                       D                                      ND                                      D                                       D                                       ND                                      ND                                      ND                                      ND                                      D                                       D                                       ND                                      ND
  Other                               P16         ND                                      ND                                     D                                       ND                                      ND                                      ND                                      D                                       ND                                      ND                                      ND                                      D                                       ND                                      ND

Patients (n = 13/17). Table shows presence or absence of biomarkers on proteomic analysis that may indicate chemotherapy response or resistance, availability of targeted therapy or clinical trials. Biomarkers are further classified on the basis of whether their absence or presence is of clinical advantage.

Beneficial.

Unlikely beneficial, otherwise uncertain clinical significance.

D: Detected; ND: Not detected.

Discussion {#S0009}
==========

Understanding the pathogenesis of GBM and its genomic landscape is paramount. This is especially true considering it is the most prevalent primary brain tumor in adults and carries a particularly malignant and aggressive course in the majority of cases. The current standard of care includes maximal surgical resection, radiation therapy and subsequent chemotherapy with an alkylating agent such as temozolomide. Despite this multidisciplinary treatment approach, median survival is still quite short at 14.6 months. This is a 3--4 months increase in median survival without any type of treatment \[[@B17],[@B18]\].

Data obtained from proteomic and genomic analysis in this study, among others, have concluded that each tumor has its own individual pathophysiologic profile. The future in treatment methodology will include identification of aberrations at a cellular level, which can allow for targeted therapies based on each tumor's particular proteogenomic identity. This has been accomplished to some degree in solid and hematologic malignancies, with directed treatment strategies against EGFR in non-small-cell lung cancer (NSCLC) and ERBB2 in breast cancer. However, this approach has not been successful in the treatment of GBM thus far.

In one study by Blumenthal *et al.*, 13 patients with GBM were treated based on results of genome sequencing. This included the utilization of EGFR tyrosine kinase inhibitors (TKI) afatinib and erlotinib. The study also treated one patient who had CDK4/6 amplification with Palbociclib. However, despite genomic sequencing and the identification of targetable genes, no significant response to tailored therapy was noticed \[[@B19]\]. This study showed that our understanding and knowledge of the molecular pathogenesis of GBM remains very limited, highlighting a need to continue our research in this domain.

Our study focused on identifying tumor heterogeneity at the cellular and molecular level for each of the 17 patients. Thus, by correlating their proteogenomic alterations with clinical course and radiographic disease advancement, we can understand how a particular tumor profile affects both prognosis and survival. Ultimately, the objective of research in the field of GBM aims to define the molecular basis of glioblastoma evolution, so that specific therapies may be developed and tailored to an individual's treatment. Our study aimed to delineate the essential biomarkers that can affect clinical outcome. Of note, this study did not aim to correlate GBM phenotype and pathologic structure with its mutation profile.

While tumor heterogeneity evidently exists between different individual patients, it is important to note that it also occurs within different areas of a single patient's tumor. In a prior study comparing primary and recurrent samples of low-grade gliomas, it was seen that in 43% cases, half the mutations seen in the primary tumor were undetectable in recurrent samples \[[@B20]\]. In our study, proteogenomic analysis was obtained to identify biomarkers that are of prognostic and predictive significance. Prognostic biomarkers aid in providing a more complete clinical picture regarding the overall survival with and without standard treatment following initial diagnosis. Predictive biomarkers help understand the potential benefits of a specific therapeutic intervention. Clinical data evaluated in the study included survival status, overall survival, relapse-free survival, treatment provided, number of relapses and treatment offered following a relapse. This information is summarized in [Table 2](#T2){ref-type="table"}. Corresponding genetic biomarkers were reviewed to assess for both prognostic and predictive significance.

The first biomarker of interest is MGMT, a DNA repair protein coded for by the *MGMT* gene. Alkylating agents, such as TMZ, result in the alkylation of this gene at O^6^ position of guanine. Such alkylation results in double-stranded DNA breaks and ultimately ends with apoptosis of the tumor cell. This action is counteracted by the DNA repair effect of the MGMT protein, leading to a less effective response to treatment \[[@B21]\]. MGMT protein was detected in samples from 13 of the 17 patients (76%) included in the study.

Amplification and overexpression of the *EGFR* gene is a distinct feature of GBM and is noticed in 40% of these tumors. On the other hand, it is rare in low-grade gliomas. There are two types of *EGFR* mutations: wild-type and EGFR variant III with the latter being the most common. EGFRvIII occurs due to deletion of exons 2 through 7 of the *EGFR* gene, resulting in an in-frame deletion in its extracellular domain \[[@B22]\]. Studies have shown EGFRvIII to be more tumorigenic than the wild-type form \[[@B23]\]. The EGFR regulates cell proliferation via signal transmission by binding EGF and TNF-α. EGFRvIII on stimulation results in the activation of intracellular pathways such as PTEN resulting in increased tumor proliferation and survival \[[@B24]\]. EGFRvIII variant is a potential target for chimeric antigen receptor T-cell (CAR-T) therapy \[[@B25]\]. CAR-T is a form of immunotherapy, which uses T lymphocytes that have been genetically altered, and allows for high binding affinity and specificity to tumor antigens. It is currently FDA approved for the treatment of acute childhood lymphoblastic lymphoma and B-cell non-Hodgkin's lymphoma \[[@B26]\]. Of particular interest were mutations in the *EGFR* gene that have previously been reported in patients with lung adenocarcinoma and have had a promising response to anti-EGFR antibodies in those patients. Response to EGFRvIII inhibitors has been very low in GBM. This suggests that complex molecular pathways need to be targeted within the EGFR system. There are also additional challenges pertaining to pharmacokinetics as any drug-targeting GBM needs to be able to cross the blood--brain barrier and then, should be able to stay in the brain parenchyma long enough to fulfill its action \[[@B27]\]. There has been conflicting data regarding the response to Erlotinib (TKI) in patients with coexpression of EGFRvIII and PTEN \[[@B28],[@B29]\]. The discordance observed in EGFR expression on genomic and proteomic analysis shows the complex relationship between signaling pathways and molecular alterations.

*TP53* is a tumor-suppressor gene that codes for a protein involved in the regulation of cell cycle, differentiation and death. Such mutations are more common in secondary GBM in comparison to primary GBM (65 vs 28%) \[[@B30]\]. Loss-of-function of normal p53 function from TP53/MDM2/MDM4/p14ARF alteration leads to clonal expansion of glioma cells \[[@B31]\]. Due to the incomplete understanding of its complexity, no clear relationship has yet been found between the p53 pathway and targetable treatments as well as outcomes of GBM \[[@B32]\].

*IDH* gene codes for isocitrate dehydrogenase, an intramitochondrial enzyme with three intracellular forms: of these, the IDH1 enzyme is involved in the production of NADPH from oxidative decarboxylation of isocitrate. NADPH has a role in protecting cells from oxidative stressors and damage. Mutations in the *IDH1* gene lead to increased tumor proliferation by activation of VEGF-mediated angiogenesis. In patients with GBM, the presence of these mutations has been noted to improve the intracellular response to TMZ when compared with individuals with the wild-type *IDH1* gene \[[@B33]\]. In a prior genomic analysis, *IDH1* gene mutations were detected in 12% of GBM tumors. It was also identified in more than 70% of patients with grade II and III astrocytomas and oligodendrogliomas, as well as in GBMs that develop from lower-grade lesions \[[@B34]\]. The presence of *IDH1* mutation has been associated with improved OS when compared with *IDH* wild-type \[[@B34]\]. In addition, in comparison to *IDH1* wild-type tumor, presence of *IDH1* mutation is associated with longer time between diagnosis of low grade or anaplastic glioma and eventual progression to GBM (66 vs 16 months). With respect to *IDH1* mutation's role in recurrent GBM, however, prior studies have shown no significant difference in PFS and OS between *IDH1* mutation and *IDH1* wild-type tumors \[[@B35]\]. In our study, two patients were found to have an *IDH1* mutation (variant p. R132H). These two patients currently have a PFS with TMZ at 11 and 28 months. Also, in each case, the tumor pathology revealed the presence of both astrocytoma and GBM.

Genomic analysis also reveals potential targetable genes, as summarized in [Table 5](#T5){ref-type="table"}. EGFR amplification and EGFR variant III were detected, which may be sensitive to medications such as an NK-EGFR, dacomitinib and rindopepimut \[[@B36]\]. In fact, dacomitinib is a kinase inhibitor recently approved by the FDA for first-line treatment of metastatic NSCLC in patients with either an *EGFR* exon 19 deletion or an exon 21 L858R mutation. This supports the possibility that these same drugs could be utilized to target the *EGFR* mutations in GBM in future.

Proteomic analysis in one patient in our study group revealed the presence of TOPO1 and hENT1. TOPO1 is a potential targetable protein for treatment with irinotecan and topotecan. hENT1 protein is a possible target for treatment with gemcitabine \[[@B37]\]. After this patient relapsed within 13 months of standard therapy with TMZ, she was treated with irinotecan and demonstrated good response with PFS at 12 months after its initiation.

At this point, the eventual clinical significance of the results of our proteomic and genomic analysis is unclear. However, presently, since molecular therapies are being developed, any information regarding molecular profiling contributes to current efforts to develop therapy tailored against pathogenic molecular processes, even though it is too preliminary to assess definite impact.

The observations made in this study highlight the importance of tumor tissue analysis and increased research in the realm of molecular studies in GBM. Understanding these complex genetic pathways and how they interact will lead to the development of effective treatment strategies that can be tailored to specific patients based on the pathologic makeup of their cancer. It also reminds us of the limitations of the current TCGA data and that there is still much to understand about the pathogenesis of GBM. Hence, this study validates the need for further research to assist in mapping specific gene and protein changes, in order to organize a detailed landscape of this deadly tumor.

Conclusion {#S0010}
==========

Proteogenomic analysis suggests that the presence of certain biological processes in each GBM will aid to classify them into groups with different biological thumbprints. Meticulous defining of aberrations at the cellular level can potentially enable for the development of targeted therapies based on an individual tumors' 'identity.' Thus, proteogenomic data are paramount to identifying potential future therapeutic targets for GBM.

Future perspective {#S0011}
==================

There have been many successes in defining molecular profiles of tumors in patients with NSCLC. This has subsequently led to identification of therapeutic targets, either at protein or gene level. These advances with NSCLC fuel hope for similar triumph to be achieved in the future for patients with GBM. As described by Lin *et al.*, retrospective analysis showed that treatment of patients with *EGFR*-mutant metastatic lung adenocarcinoma with EGFR-TKI improved 5-year survival rates from less than 5% to as high as 14.6% \[[@B38]\]. This study also highlighted that certain proteogenomic attributes, such as the presence of an exon 19 deletion, were associated with improved outcomes in NSCLC patients. With continued investigations to extract clinically significant proteomic and genomic data, new diagnostic, prognostic and predictive biomarkers may be identified for GBM in the near future in addition to already known molecular markers such as EGFR, PIK3R1 and PTEN that will serve as targets for a novel generation of therapies against GBM. While limited therapeutic success has been achieved in trials that have used therapies against known oncogenic pathways thus far, as greater information is accumulated regarding GBM pathogenesis and classification of aberrant genes, we anticipate that development of therapies, such as targeted immunotherapies, will be developed over the next few years. Current genomic sequencing techniques allow for accumulation of large pools of data. If applied clinically, this information provides positive prospects to achieve better outcomes in patients with GBM. Given heterogeneity of GBM, it remains essential that all information gathered by a GBM analysis in individual studies is incorporated into our current available knowledge. This can then serve as a resource on which future studies can be built upon.

###### Summary points

-   Glioblastoma multiforme (GBM) is the most frequent primary brain tumor, which has an aggressive clinical course and extremely poor prognosis. Given limited success of the current standard of care that combines surgery, chemotherapy and radiation, the search for more effective therapies is critical. Thus, understanding the molecular pathogenesis of GBM, and classifying these data into a pool of organized information can allow for the development of novel treatment agents.

-   Proteogenomic analysis in our study revealed *TP53*, *EGFR*, *PIK3R1*, *PTEN*, *NF1*, *RET* and *STAG2* as significantly mutated genes in these aggressive tumors.

-   *EGFR* alterations seen included EGFRvIII expression, L816Q *EGFR* missense mutation on exon 21 and EGFR fusion (FGFR3-TACC3); all three are potential therapeutic targets of novel agents including EGFRvIII-specific dendritic cell vaccine, EGFR inhibitors and FGFR inhibitors.

-   *TP53* mutation was found in 30% of patients, including in COSMIC hotspot driver gene as well as accompanying *IDH1* and *ATRX* mutations suggesting transformation from low- to high-grade glioma.

-   One patient had a high mutation burden, currently living after 12 months of diagnosis.

-   Proteomics showed significantly higher (n = 9, 53%) EGFR expression than genomic expression (53 vs 23%), suggesting tumor heterogeneity. 75% were methyl guanine methyl transferase-methylated, a predictive marker of response to temozolomide chemotherapy.

-   At this point, while the eventual clinical significance of the results of our proteomic and genomic analysis in unclear, any information regarding molecular profiling contributes to current efforts to develop therapy tailored against pathogenic molecular processes.

-   Further research is required to completely comprehend the specific genetic and protein changes underlying the development of GBM.
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